Core Points - The USANA Foundation, in collaboration with community partners, organized an event to assemble 3,000 food bags for families facing food insecurity in Utah, particularly in response to recent federal SNAP cutbacks [1][2][3] - The event took place at the USANA Foundation Headquarters and involved hundreds of volunteers from various organizations, showcasing community unity and compassion [2][3] - The initiative aims to provide immediate relief to families affected by the reduction in SNAP benefits, with the bags set to be distributed to local school districts and food pantries [3][4] Group 1 - The USANA Foundation's mission focuses on ensuring families have access to essential nutrition, emphasizing the need for continued support beyond short-term relief efforts [4][5] - The organization has a history of providing hundreds of millions of meals globally, supported by donations from employees and the public [5] - The event highlighted the collaboration between different organizations and individuals to strengthen the community and support families in crisis [3][4] Group 2 - The USANA Foundation encourages public donations to sustain its efforts in providing essential nutrition to children facing hunger [4] - USANA, the parent company of the foundation, has been in the nutrition and lifestyle products industry for over 30 years, committed to empowering healthier living [6]

Core Insights - LifeVantage Corporation reported a revenue of $47.6 million for the first quarter of fiscal 2026, reflecting a 0.7% increase year-over-year [5][10] - The company is focusing on the strategic acquisition of LoveBiome, which positions it as a leader in the natural GLP-1 activation and microbiome health markets [4] - The company expects revenue growth to accelerate in the second half of the fiscal year due to seasonality and the impact of the LoveBiome acquisition [15] Financial Performance - Revenue for the first quarter of fiscal 2026 was $47.6 million, a 0.7% increase from the same period in fiscal 2025 [5][10] - Gross profit was $37.8 million, representing 79.5% of revenue, slightly down from 79.9% in the previous year [6] - Net income for the first quarter was $2.2 million, or $0.17 per diluted share, compared to $1.8 million, or $0.14 per diluted share in the prior year [10][11] Expense Analysis - Commissions and incentives expense increased to $20.7 million, or 43.5% of revenue, up from 43.0% in the previous year [7] - Selling, general and administrative (SG&A) expenses were $14.9 million, or 31.2% of revenue, slightly down from 31.4% in the prior year [8] - Adjusted EBITDA for the first quarter was $3.9 million, compared to $4.4 million in the same period last year [11] Balance Sheet & Liquidity - The company used $2.3 million of cash from operations during the first three months of fiscal 2026, compared to $0.6 million in the same period of fiscal 2025 [12] - Cash and cash equivalents at September 30, 2025, were $13.1 million, down from $20.2 million at June 30, 2025 [12] Shareholder Returns - LifeVantage repurchased 44,000 common shares for approximately $0.6 million during the first quarter [13] - A cash dividend of $0.045 per common share was declared, to be paid on December 15, 2025 [14] Guidance - The company reiterated its revenue guidance for fiscal 2026 in the range of $225 million to $240 million, with adjusted EBITDA expected between $23 million and $26 million [15]

Core Insights - LifeVantage Corporation successfully concluded Momentum Academy 2025, an event aimed at empowering Consultants and enhancing business engagement [1][5] - The event marked the first integration of LoveBiome Consultants with LifeVantage, fostering collaboration and alignment between the two companies [2][5] Event Overview - Momentum Academy 2025 took place from October 23-25 at the Hilton Anatole in Dallas, TX, under the theme "Love Life & Drive" [1][2] - The event featured workshops, seminars, and keynotes focused on business acceleration, leadership potential, enrollment, retention, and advancement strategies [3] Product Launch - Attendees were introduced to Healthy Edge, combining Protandim® Nrf2 Synergizer with LoveBiome P84, aimed at supporting cellular health [4] - This event marked the first opportunity for Consultants and consumers to purchase LoveBiome P84 directly through LifeVantage, alongside other exclusive products [4] Company Vision - The President and CEO of LifeVantage emphasized the importance of unity and empowerment among Consultants, highlighting the innovative spirit of the company [5] - LifeVantage positions itself as a pioneer in nutrigenomics, focusing on products that activate health at the cellular level [7]

Core Insights - LifeVantage Corporation, a health and wellness company, will have its CEO Steve Fife participate in the LD Micro Main Event XIX from October 19-21, 2025 [1] - Fife's presentation is scheduled for October 20, 2025, at approximately 5:30 p.m. Eastern Time, with a live webcast available for investors [2] Company Overview - LifeVantage Corporation specializes in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and various health-supporting nutrients [3] - Founded in 2003 and headquartered in Lehi, Utah, LifeVantage operates through independent consultants who sell products and promote business opportunities [3]

Group 1 - LifeVantage Corporation will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with CEO Steve Fife and CFO Carl Aure presenting [1][2] - The presentation is scheduled for approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's Investor Relations website [2] - LifeVantage specializes in nutrigenomics, offering products that activate health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] Group 2 - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, focusing on health and wellness products that work with individual biology [3] - The company also provides a business opportunity for independent consultants to sell its products and promote entrepreneurship [3]

Core Insights - LifeVantage Corporation will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York [1] - The company's President and CEO, Steve Fife, along with CFO Carl Aure, will present to investors on September 10, 2025, at approximately 1:00 p.m. Eastern Time [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [3] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, with a business model that includes independent consultants selling products and sharing business opportunities [3]

Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation is set to launch its products in Iceland in September 2025, marking a significant step in its international expansion strategy [1][4] - The launch will feature a selection of top-performing products and three curated wellness stacks tailored to various health goals, with plans for additional products in the future [2][4] - The introduction of the LifeVantage business opportunity in Iceland will be supported by the Evolve Compensation Plan, allowing consultants to enroll for the launch [3][4] Company Overview - LifeVantage Corporation specializes in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [6] - The company's product line includes scientifically validated activators such as Protandim®, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [6][7] - LifeVantage operates through independent consultants who sell products and promote business opportunities to aspiring entrepreneurs [6] Leadership Perspective - Steve Fife, President and CEO, expressed excitement about the Iceland launch, emphasizing its role in empowering individuals with health tools and supporting their entrepreneurial journeys [4]

Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, which was just above the midpoint of the guidance range [9][28] - On a constant currency basis, net sales grew by 1.4% year over year, marking the second consecutive quarter of growth excluding foreign exchange headwinds [10][28] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [29][38] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [10][33] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [11] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, primarily due to pricing actions and reduced input costs [29] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, driven by favorable pricing and a 4% increase in volumes [35] - North America saw a 4% decline in net sales year over year, primarily due to an 8% reduction in volumes [37] - China experienced a 14% decline in net sales year over year on a reported basis, driven by a 14% decrease in volumes [37] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its network of 2.1 million distributors and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in the market and enhance its product portfolio [12][21] - The focus will be on innovation, operational excellence, and sustainable growth, with an emphasis on AI-powered solutions and personalized health programs [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][9] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [43][45] - The outlook for Q2 2025 includes expectations for net sales to be in the range of down 3.5% to up 0.5% year over year, with a constant currency basis expecting a range of down 0.5% to up 3.5% [44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [42] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol and its impact on conversion rates at U.S. Nutrition clubs? - Management acknowledged that it is early to discuss ROI but emphasized the potential for the digital platform to enhance product consumption and distributor engagement [49][50] Question: What is driving the sequential decline in distributor numbers and volumes in North America? - Management noted that the U.S. market started strong but faced challenges in February, with expectations for improvement in Q2 [60][62] Question: Why was the midpoint of the constant currency sales guidance for 2025 reduced? - Management explained that the reduction reflects the Q1 trend and some weakness in Asia Pacific, particularly in China, while still expecting overall growth [64][66] Question: What are the intentions for Link Biosciences and its target audience? - Management indicated that Link Biosciences will cater to both athletes and a broader audience seeking customized health solutions, positioning the company ahead of competitors [70][74] Question: How does the current economic environment impact the business? - Management suggested that direct sellers historically perform well in cyclical environments where consumers seek additional income [87]

Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, but showed a constant currency growth of 1.4% year over year [10][27] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [28] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [11][31] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [12] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, driven by pricing actions and reduced input costs [28] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, with a 4% increase in volumes [33] - EMEA net sales were down 2% year over year on a reported basis, while up 3% on a local currency basis, with a 5% decline in volume [34] - North America saw a 4% decrease in net sales year over year, primarily due to an 8% reduction in volumes [35] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its distributor network and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in personalized health solutions [13][21] - The focus will be on innovation, operational excellence, and sustainable growth rather than just short-term gains [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][8] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [40][43] - The outlook for Q2 2025 includes expected net sales to range from down 3.5% to up 0.5% year over year, with a constant currency basis expectation of down 0.5% to up 3.5% [41][44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [39] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol? - Management indicated that it is early to discuss ROI, but the digital platform aims to support product consumption and distributor engagement [47][50] Question: What is driving the sequential decline in distributor KPIs in North America? - Management noted that the quarter started strong but faced challenges in February, with expectations for improvement in Q2 [61][63] Question: Why was the constant currency sales guidance for 2025 reduced? - The reduction was primarily due to rolling in Q1 trends, with some weakness noted in Asia Pacific and cautious expectations for China [66][67] Question: What are the intentions for Link Biosciences? - The company aims to target both athletes and a more general audience, focusing on hyper-customization in health products [71][75] Question: Is there any additional CapEx associated with the recently acquired assets? - Management confirmed that the CapEx guidance was lowered due to underspending in Q1, but future months will include necessary expenditures for the acquisitions [92][93]